SIU Physicians and Surgeons: Where Knowledge is Quality

Submit New Study Information

RTOG 0229 -- A Phase 11 Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed By Surgical Resection and Consolidation Therapy for Locally Advanced Non -- Small Cell Lung Carcinoma

Purpose of trial:

The purpose of this study is to find out what effects the combination of chemotherapy and high doses of radiation therapy followed by surgery and chemotherapy have on lung cancer. Surgery after chemotherapy and radiation is done to remove any remaining cancer and to decrease the risk of the cancer! returning in the lung. We wish to determine if using high dose radiation (with chemotherapy) increases control of lung cancer prior to surgery and because we need to find out if the combination of chemotherapy, high dose radiation, and surgery is safe

Protocol Summary:

Patients will receive two kinds of chemotherapy (Paclitaxel and Carboplatin) through a vein once a week for six weeks. Along with the chemotherapy, they will receive radiation therapy once a day for about seven weeks. Within 8 weeks after the chemotherapy and radiation is finished, some patients will have surgery to remove all or most of the lung cancer. Patients whose cancer has progressed after chemotherapy and radiation will not have the surgery. . Additional chemotherapy will be given to all patients, those who had surgery and those who did not have surgery. They will be given the same chemotherapy drug through the vein every 21 days for 2 treatments. If they have surgery, they will start this chemotherapy about 4 weeks after the chemotherapy and radiation therapy is completed. If the patient does have surgery they will start the chemotherapy no more than 10 weeks after the surgery. There will be physical examinations and testing done periodically while in the study. Patients will be in the study for a total of 5 years. This study is sponsored by the Radiation Therapy Oncology Group of the American College of Radiology

Sponsoring Department: Surgery - Division of Cardiothoracic Surgery
Sponsoring Company: Radiation Therapy Oncology Group of the American College of Radiology
Investigator: Stephen R. Hazelrigg, MD
Number of other sites in trial: SIU School of Medicine; Memorial Medical Center, St. John's Hospital
Basic Eligibility Criteria: Participants must have histological proof of non-small cell lung cancer documented by biopsy or cytology
Age: 18 years of age or older
Study Coordinator:  
Number of visits required:  
SCHIRS Protocol Number:  
Contact Person: Contact Person: Theresa Boley, RN, MSN, APN/FNP
Contact Phone: 217-545-5000
Contact Email: tboley@siumed.edu

Click here to return to the previous page

Return to top of page

Click here to send questions or comments about this site via e-mail.

Updated May 10, 2006